Xiao Z F, Zou S S, Yi C F, Zhao Y, Wu L S, Feng Y H
Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.
Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China Department of Hematology, The Tenth Affiliated Hospital, Southern-Medical University (Dongguan People's Hospital), Dongguan 523000, China.
Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):672-677. doi: 10.3760/cma.j.cn121090-20231230-00349.
To study the expressions of C-C class chemokine 17 (CCL17), C-C class chemokine 22 (CCL22), and C-C chemokine receptor 4 (CCR4) in newly diagnosed multiple myeloma (NDMM) for analyzing their correlations with clinical features and to preliminarily explore their roles in the development of NDMM. The study included 40 patients with NDMM and 20 healthy volunteers from the Department of Hematology of the Affiliated Hospital of Zunyi Medical University from July 2020 to December 2022. Peripheral blood, bone marrow, and bone marrow biopsy tissue samples were collected from the two groups. The expression levels of CCL17, CCL22, and CCR4 in patients with NDMM were analyzed using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry. The mRNA expression levels of CCL17, CCL22, and CCR4 in the bone marrow mononuclear cell (BMMNC) of patients with NDMM were analyzed to assess their correlations with clinical indicators. The mRNA expression levels of CCL17, CCL22, and CCR4 in BMMNC were higher in patients with NDMM than in controls (all <0.05). The protein expression levels of CCL17 and CCL22 in peripheral blood supernatants and bone marrow supernatants were higher in patients with NDMM than in controls (all <0.05). The expression levels of CCL17, CCL22, and CCR4 in bone marrow biopsy tissues were higher in patients with NDMM than in controls (all <0.05). The mRNA expression level of CCL17 was increased in NDMM patients with combined anemia, bone damage, renal damage, and M protein level ≥30 g/L (all <0.05). The mRNA expression level of CCL22 was increased in NDMM patients with combined anemia, bone damage, and renal damage (all <0.05). The mRNA expression level of CCR4 was increased in NDMM patients with combined anemia and renal damage (all <0.05) . CCL17, CCL22, and CCR4 were highly expressed in clinical samples from patients with NDMM compared to those from controls, and they may be involved in the occurrence and development of NDMM.
研究新诊断多发性骨髓瘤（NDMM）中C-C类趋化因子17（CCL17）、C-C类趋化因子22（CCL22）和C-C趋化因子受体4（CCR4）的表达情况，分析其与临床特征的相关性，并初步探讨它们在NDMM发生发展中的作用。本研究纳入了2020年7月至2022年12月期间遵义医科大学附属医院血液科的40例NDMM患者和20名健康志愿者。采集两组的外周血、骨髓及骨髓活检组织样本。采用实时定量逆转录聚合酶链反应（RQ-PCR）、酶联免疫吸附测定（ELISA）和免疫组织化学方法分析NDMM患者中CCL17、CCL22和CCR4的表达水平。分析NDMM患者骨髓单个核细胞（BMMNC）中CCL17、CCL22和CCR4的mRNA表达水平，以评估其与临床指标的相关性。NDMM患者BMMNC中CCL17、CCL22和CCR4的mRNA表达水平高于对照组（均P<0.05）。NDMM患者外周血上清液和骨髓上清液中CCL17和CCL22的蛋白表达水平高于对照组（均P<0.05）。NDMM患者骨髓活检组织中CCL17、CCL22和CCR4的表达水平高于对照组（均P<0.05）。合并贫血、骨损害、肾损害且M蛋白水平≥30 g/L的NDMM患者中CCL17的mRNA表达水平升高（均P<0.05）。合并贫血、骨损害和肾损害的NDMM患者中CCL22的mRNA表达水平升高（均P<0.05）。合并贫血和肾损害的NDMM患者中CCR4的mRNA表达水平升高（均P<0.05）。与对照组相比，CCL17、CCL22和CCR4在NDMM患者的临床样本中高表达，它们可能参与了NDMM的发生发展。
